Form DEFR14A - Revised definitive proxy soliciting materials:
SEC Accession No. 0001641172-25-011526
Filing Date
2025-05-19
Accepted
2025-05-19 17:26:41
Documents
23

Document Format Files

Seq Description Document Type Size
1 DEFR14A formdefr14a.htm   iXBRL DEFR14A 729058
2 GRAPHIC formdefr14a_001.jpg GRAPHIC 10758
3 GRAPHIC formdefr14a_002.jpg GRAPHIC 10758
4 GRAPHIC formdefr14a_003.jpg GRAPHIC 58474
5 GRAPHIC formdefr14a_004.jpg GRAPHIC 55200
6 GRAPHIC proxy_001.jpg GRAPHIC 656155
7 GRAPHIC proxy_002.jpg GRAPHIC 415223
  Complete submission text file 0001641172-25-011526.txt   4521797

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE tnfa-20241231.xsd EX-101.SCH 6529
9 XBRL DEFINITION FILE tnfa-20241231_def.xml EX-101.DEF 11755
10 XBRL LABEL FILE tnfa-20241231_lab.xml EX-101.LAB 67787
11 XBRL PRESENTATION FILE tnfa-20241231_pre.xml EX-101.PRE 44371
26 EXTRACTED XBRL INSTANCE DOCUMENT formdefr14a_htm.xml XML 149613
Mailing Address 1185 AVENUE OF THE AMERICAS SUITE 249 NEW YORK NY 10036
Business Address 1185 AVENUE OF THE AMERICAS SUITE 249 NEW YORK NY 10036 856-848-8698
TNF Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFR14A | Act: 34 | File No.: 001-36268 | Film No.: 25965200
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)